Abstract
Hypertriglyceridemia (HTG) is known as a common metabolic disorder associated with increased production, decrease catabolism and/or decreased hepatic uptake of triglyceride (TG)-rich particles. We assessed, in the Québec City population, the allele frequency and haplotype distributions of mutations in genes related to HTG, such as the apolipoprotein E (APOE) (C112R and C158R), the apolipoprotein CIII (APOC3) (C-482T and C3238G) and the peroxisome proliferator-activated receptor alpha (PPARα) (L162V) genes. A total of 938 anonymous unlinked newborns from the metropolitan Québec City area have been genotyped. Allele frequencies observed in the Québec City population differed from known frequencies determined in other Caucasian populations. The co-transmitted allele distribution between the two-marker genotypes APOE/APOC3(C3238G) and APOC3(C-482T)/PPARα(L162V) presented a weak deviation from the assumption of genetic independence. Also, we observed a non-independent distribution of the T-482/G3238 allele combinations within the APOC3 gene, suggesting strong linkage disequilibrium between the C-482T and C3238G polymorphisms. Moreover, comparisons of allele frequencies observed in the population of Québec City to those obtained in other Caucasian populations suggested that the population of Québec City may be at a lower risk of developing HTG due to APOE, APOC3 and PPARα genetic variants. However, the strong linkage disequilibrium and the two-marker genotype distributions observed in the APOC3 gene suggest that these two variants may functionally interact in the Québec City population.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bailleul S, Couderc R, Landais V, Lefevre G, Raichvarg D, Etienne J (1993) Direct phenotyping of human apolipoprotein E in plasma: application to population frequency distribution in Paris (France). Hum Hered 43:159–165
Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435
Brisson D, Vohl MC, Hudson TJ, Gaudet D (2001) Effects of the PPARalpha-L162V missense mutation and other genotypes on cholesterol and triglyceride contents of lipoprotein subfractions. Can J Cardiol 17:95C
Brisson D, Ledoux K, Bosse Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D (2002) Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 12:313–320
Brzustowicz LM, Merette C, Xie X, Townsend L, Gilliam TC, Ott J (1993) Molecular and statistical approaches to the detection and correction of errors in genotype databases. Am J Hum Genet 53:1137–1145
Corella D, Guillén M, Saiz C, Portolés O, Sabater A, Folch J, Ordovas JM (2002) Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population. Interaction with tobacco smoking and the apoe locus. J Lipid Res 43:416–427
Cumming AM, Robertson FW (1984) Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet 25:310–313
Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu X, Lusis AJ, de Bruin TW (1997) Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J Clin Invest 99:953–961
Dallongeville J, Lussier-Cacan S, Davignon J (1992) Modulation of plasma triglyceride levels by apoE phenotype: a meta- analysis. J Lipid Res 33:447–454
Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N (2000) Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis 150:149–157
Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N (2001) Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans. Int J Obes Relat Metab Disord 25:1012–1017
Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL (1993) An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A 90:4562–4566
Davignon J, Cohn JS (1996) Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 124(Suppl):S57–S64
Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA (2001) A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med 79:198–204
Galetto R, Albajar M, Polanco JI, Zakin MM, Rodriguez-Rey JC (2001) Identification of a peroxisome-proliferator-activated-receptor response element in the apolipoprotein E gene control region. Biochem J 357:521–527
Gerdes LU, Klausen IC, Sihm I, Faergeman O (1992) Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol 9:155–167
Groenendijk M, Cantor R, De Bruin T, Dallinga-Thie G (2001) New genetic variants in the apoA-I and apoC-III genes and familial combined hyperlipidemia. J Lipid Res 42:188–194
Hegele RA, Brunt JH, Connelly PW (1995) Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol 15:861–871
Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B (1997) Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 17:2753–2758
Hertz R, Bishara-Shieban J, Bar-Tana J (1995) Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 270:13470–13475
Heyer E, Tremblay M (1995) Variability of the genetic contribution of Quebec population founders associated to some deleterious genes. Am J Hum Genet 56:970–978
Hill JS, Pritchard PH (1990) Improved phenotyping of apolipoprotein E: application to population frequency distribution. Clin Chem 36:1871–1874
Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548
Hoffer MJ, Sijbrands EJ, De Man FH, Havekes LM, Smelt AH, Frants RR (1998) Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur J Clin Invest 28:807–812
Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484
Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T (1995) Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 96:2601–2605
Mann CJ, Troussard AA, Yen FT, Hannouche N, Najib J, Fruchart JC, Lotteau V, André P, Bihain BE (1997) Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem 272:31348–31354
McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS (1992) Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 33:995–1003
Morrison AC, Ballantyne CM, Bray M, Chambless LE, Sharrett AR, Boerwinkle E (2002) LPL polymorphism predicts stroke risk in men. Genet Epidemiol 22:233–242
Murthy V, Julien P, Gagné C (1996) Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther 70:101–135
Ogami K, Hadzopoulou-Cladaras M, Cladaras C, Zannis VI (1990) Promoter elements and factors required for hepatic and intestinal transcription of the human ApoCIII gene. J Biol Chem 265:9808–9815
Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, Pocovi M, Frossard PM, Masharani U, Wilson PW et al (1991) Restriction fragment length polymorphisms of the apolipoprotein A-I, C- III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 87:75–86
Price WH, Morris SW, Kitchin AH, Wenham PR, Burgon PR, Donald PM (1989) DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. Lancet 1:1407–1411
Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE (1983) DNA polymorphism adjacent to human apoprotein A-1 gene: relation to hypertriglyceridaemia. Lancet 1:444–446
Robitaille N, Cormier G, Couture R, Bouthillier D, Davignon J, Pérusse L (1996) Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. Hum Biol 68:357–370
Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336–5348
Sheehan D, Bennett T, Cashman K (2000) Apolipoprotein E gene polymorphisms and serum cholesterol in healthy Irish adults: a proposed genetic marker for coronary artery disease risk. Ir J Med Sci 169:50–54
Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, Gilligan M, Gambert P, Ball MJ (1991) Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 87:239–247
Shoulders CC, Grantham TT, North JD, Gaspardone A, Tomai F, de Fazio A, Versaci F, Gioffre PA, Cox NJ (1996) Hypertriglyceridemia and the apolipoprotein CIII gene locus:lack of association with the variant insulin response element in Italian school children. Hum Genet 98:557–566
Sing CF, Davignon J (1985) Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37:268–285
Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E (1996) Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 16:941–947
Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM (2002) Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 22:805–810
Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE (2002) Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11:3039–3046
Tas S (1989) Strong association of a single nucleotide substitution in the 3′- untranslated region of the apolipoprotein-CIII gene with common hypertriglyceridemia in Arabs. Clin Chem 35:256–259
Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde G, Cellier C, Faith JM, Després JP, Morgan K, Hudson TJ (2000) Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 41:945–952
Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P (1999) ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 99:1872–1877
Waterworth DM, Hubacek JA, Pitha J, Kovar J, Poledne R, Humphries SE, Talmud PJ (2000) Plasma levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI-APOE cluster. J Lipid Res 41:1103–1109
Xhignesse M, Lussier-Cacan S, Sing CF, Kessling AM, Davignon J (1991) Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb 11:1100–1110
Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J (1995) An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet 95:371–375
Zhang Q, Liu Y, Liu BW, Fan P, Cavanna J, Galton DJ (1998) Common genetic variants of lipoprotein lipase and apolipoproteins AI- CIII that relate to coronary artery disease: a study in Chinese and European subjects. Mol Genet Metab 64:177–183
Zhao JH, Curtis D, Sham PC (2000) Model-free analysis and permutation tests for allelic associations. Hum Hered 50:133–139
Acknowledgements
We thank Mrs. É. Gravel for her expert technical assistance in managing blood samples and for DNA purification, and Mr. G. Cardinal and Dr. S. Giroux for their help in ASO designing and statistical analysis. Dr. C. Garenc was the recipient of a post-doctoral fellowship from the “Centre de Recherche sur le Métabolisme Energétique (CREME)”. Dr. M.C. Vohl was the recipient of a scholarship from the FRSQ. Dr. P. Julien was supported by grants from the Canadian Institutes of Health Research (CIHR, MOP 37907), Cardiovascular Health Network of the FRSQ and Heart and Stroke Foundation of Canada. Dr. F. Rousseau is an FRSQ national scientist.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garenc, C., Aubert, S., Laroche, J. et al. Population prevalence of APOE, APOC3 and PPAR-α mutations associated to hypertriglyceridemia in French Canadians. J Hum Genet 49, 691–700 (2004). https://doi.org/10.1007/s10038-004-0208-6
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-004-0208-6
Keywords
This article is cited by
-
Sequence analysis and variant identification at the APOC3 gene locus indicates association of rs5218 with BMI in a sample of Kuwaiti’s
Lipids in Health and Disease (2019)
-
Interactions of the apolipoprotein C-III 3238C>G polymorphism and alcohol consumption on serum triglyceride levels
Lipids in Health and Disease (2010)
-
The combination of ApoCIII, hepatic lipase and hormono sensitive lipase gene polymorphisms suggests an association with susceptibility to gestational hypertension
Journal of Human Genetics (2007)
-
Effect of the APOC3 Sst I SNP on fasting triglyceride levels in men heterozygous for the LPL P207L deficiency
European Journal of Human Genetics (2005)
